Connection

WILLIAM G WIERDA to Clinical Trials as Topic

This is a "connection" page, showing publications WILLIAM G WIERDA has written about Clinical Trials as Topic.
Connection Strength

0.584
  1. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. 2020 05 21; 135(21):1859-1869.
    View in: PubMed
    Score: 0.085
  2. Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia? Clin Adv Hematol Oncol. 2019 Apr; 17(4):214-216.
    View in: PubMed
    Score: 0.079
  3. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. J Natl Compr Canc Netw. 2019 Jan; 17(1):12-20.
    View in: PubMed
    Score: 0.077
  4. The use of obinutuzumab in chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2014 Jun; 12(6):395-7.
    View in: PubMed
    Score: 0.056
  5. Richter's transformation in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2007 Oct; 2(4):265-71.
    View in: PubMed
    Score: 0.035
  6. Gene therapy and active immune therapy of hematologic malignancies. Best Pract Res Clin Haematol. 2007 Sep; 20(3):557-68.
    View in: PubMed
    Score: 0.035
  7. Initial therapy for patients with chronic lymphocytic leukemia. Semin Oncol. 2006 Apr; 33(2):202-9.
    View in: PubMed
    Score: 0.032
  8. Current and investigational therapies for patients with CLL. Hematology Am Soc Hematol Educ Program. 2006; 285-94.
    View in: PubMed
    Score: 0.031
  9. Novel immune-based treatment strategies for chronic lymphocytic leukemia. J Clin Oncol. 2005 Sep 10; 23(26):6325-32.
    View in: PubMed
    Score: 0.031
  10. Evolution of treatment strategies in chronic lymphocytic leukemia. Part 2 of a 3-Part series: Advances in the treatment of hematologic malignancies. Clin Adv Hematol Oncol. 2005 Aug; 3(8):1-10; quiz 11-2.
    View in: PubMed
    Score: 0.030
  11. Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. Cancer. 2017 02 15; 123(4):609-616.
    View in: PubMed
    Score: 0.017
  12. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. Lancet Haematol. 2015 Mar; 2(3):e118-28.
    View in: PubMed
    Score: 0.015
  13. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015 Mar 26; 125(13):2062-7.
    View in: PubMed
    Score: 0.015
  14. CARs in chronic lymphocytic leukemia -- ready to drive. Curr Hematol Malig Rep. 2013 Mar; 8(1):60-70.
    View in: PubMed
    Score: 0.013
  15. Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Mod Pathol. 2012 Feb; 25(2):237-45.
    View in: PubMed
    Score: 0.012
  16. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer. 2011 Sep 01; 117(17):3999-4008.
    View in: PubMed
    Score: 0.011
  17. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer. 2009 Aug 15; 115(16):3709-18.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.